{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T10:08:18Z","timestamp":1747390098946,"version":"3.40.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004718","name":"Universit\u00e9 de Toulouse","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004718","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s11523-025-01131-x","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T06:16:22Z","timestamp":1741846582000},"page":"311-317","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Compassionate Access to Brigatinib for Patients with Non-small-cell Lung Cancer Harboring a ROS1 Rearrangement: Results from the BRIGAROS Study"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0057-7424","authenticated-orcid":false,"given":"Jean","family":"Mourlanette","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaelle","family":"Rousseau-Bussac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siham","family":"Mallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Guisier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard","family":"Zalcman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9mi","family":"Veillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clarisse","family":"Audigier-Valette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magali","family":"Roa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Nicolle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helene","family":"Doubre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Cloarec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9gine","family":"Lamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugues","family":"Morel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubert","family":"Curcio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lie","family":"Lagrange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Schott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marielle","family":"Sabatini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Claire","family":"Toffart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Pinsolle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaafar","family":"Bennouna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Chouaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5921-7613","authenticated-orcid":false,"given":"Julien","family":"Mazieres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"issue":"4","key":"1131_CR1","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1586\/era.12.17","volume":"12","author":"S-HI Ou","year":"2012","unstructured":"Ou S-HI, Tan J, Yen Y, Soo RA. ROS1 as a \u2018druggable\u2019 receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway. Expert Rev Anticancer Ther. 2012;12(4):447\u201356.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"16","key":"1131_CR2","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1158\/1078-0432.CCR-12-1812","volume":"18","author":"M Stumpfova","year":"2012","unstructured":"Stumpfova M, J\u00e4nne PA. Zeroing in on ROS1 Rearrangements in Non-Small Cell Lung Cancer. Clin Cancer Res. 2012;18(16):4222\u20134.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"1131_CR3","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","volume":"30","author":"K Bergethon","year":"2012","unstructured":"Bergethon K, Shaw AT, Ou S-HI, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30(8):863\u201370.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1131_CR4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jmoldx.2017.11.004","volume":"20","author":"NI Lindeman","year":"2018","unstructured":"Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the college of american pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Mol Diagn. 2018;20(2):129\u201359.","journal-title":"J Mol Diagn"},{"issue":"7","key":"1131_CR5","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/annonc\/mdz131","volume":"30","author":"AT Shaw","year":"2019","unstructured":"Shaw AT, Riely GJ, Bang Y-J, et al. Crizotinib in ROS1-rearranged advanced non- small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol. 2019;30(7):1121\u20136.","journal-title":"Ann Oncol"},{"issue":"9","key":"1131_CR6","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1200\/JCO.2014.58.3302","volume":"33","author":"J Mazi\u00e8res","year":"2015","unstructured":"Mazi\u00e8res J, Zalcman G, Crin\u00f2 L, et al. Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort. J Clin Oncol. 2015;33(9):992\u20139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1131_CR7","first-page":"3466","volume":"17","author":"Y-C Zhu","year":"2019","unstructured":"Zhu Y-C, Zhang X-G, Lin X-P, et al. Clinicopathological features and clinical efficacy of crizotinib in Chinese patients with ROS1-positive non-small cell lung cancer. Oncol Lett. 2019;17(3):3466\u201374.","journal-title":"Oncol Lett"},{"issue":"7","key":"1131_CR8","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.jtho.2019.03.020","volume":"14","author":"S Michels","year":"2019","unstructured":"Michels S, Massut\u00ed B, Schildhaus H-U, et al. Safety and efficacy of crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): a European Phase II Clinical Trial. J Thorac Oncol. 2019;14(7):1266\u201376.","journal-title":"J Thorac Oncol"},{"issue":"12","key":"1131_CR9","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1093\/annonc\/mdz407","volume":"30","author":"D Moro-Sibilot","year":"2019","unstructured":"Moro-Sibilot D, Cozic N, P\u00e9rol M, et al. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcS\u00e9 phase II trial. Ann Oncol. 2019;30(12):1985\u201391.","journal-title":"Ann Oncol"},{"issue":"23","key":"1131_CR10","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1200\/JCO.2016.71.3701","volume":"35","author":"SM Lim","year":"2017","unstructured":"Lim SM, Kim HR, Lee J-S, et al. Open-label, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement. J Clin Oncol. 2017;35(23):2613\u20138.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1131_CR11","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1470-2045(19)30690-4","volume":"21","author":"A Drilon","year":"2020","unstructured":"Drilon A, Siena S, Dziadziuszko R, et al. Entrectinib in ROS1 fusion-positive non- small-cell lung cancer: integrated analysis of three phase 1\u20132 trials. Lancet Oncol. 2020;21(2):261\u201370.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1131_CR12","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2302299","volume":"390","author":"A Drilon","year":"2024","unstructured":"Drilon A, Camidge DR, Lin JJ, et al. Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer. N Engl J Med. 2024;390(2):118\u201331.","journal-title":"N Engl J Med"},{"issue":"12","key":"1131_CR13","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S1470-2045(19)30655-2","volume":"20","author":"AT Shaw","year":"2019","unstructured":"Shaw AT, Solomon BJ, Chiari R, et al. Lorlatinib in advanced ROS1-positive non- small-cell lung cancer: a multicentre, open-label, single-arm, phase 1\u20132 trial. Lancet Oncol. 2019;20(12):1691\u2013701.","journal-title":"Lancet Oncol"},{"key":"1131_CR14","doi-asserted-by":"crossref","unstructured":"Gainor JF, Tseng D, Yoda S, et al. Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non\u2013Small-Cell Lung Cancer. JCO Precis Oncol. 2017; p. PO.17.00063.","DOI":"10.1200\/PO.17.00063"},{"issue":"22","key":"1131_CR15","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1158\/1078-0432.CCR-16-0569","volume":"22","author":"S Zhang","year":"2016","unstructured":"Zhang S, Anjum R, Squillace R, et al. The Potent ALK Inhibitor Brigatinib (AP26113) overcomes mechanisms of resistance to first- and second-generation alk inhibitors in preclinical models. Clin Cancer Res. 2016;22(22):5527\u201338.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1131_CR16","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.bulcan.2020.05.008","volume":"107","author":"A Mansuet-Lupo","year":"2020","unstructured":"Mansuet-Lupo A, Garinet S, Damotte D, et al. Les r\u00e9arrangements mol\u00e9culaires\u202f: cibles th\u00e9rapeutiques en canc\u00e9rologie thoracique. Bull Cancer (Paris). 2020;107(9):896\u2013903.","journal-title":"Bull Cancer (Paris)."},{"issue":"1","key":"1131_CR17","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1158\/1078-0432.CCR-14-1385","volume":"21","author":"R Katayama","year":"2015","unstructured":"Katayama R, Kobayashi Y, Friboulet L, et al. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer. Clin Cancer Res. 2015;21(1):166\u201374.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1131_CR18","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1158\/1078-0432.CCR-15-1601","volume":"23","author":"CR Chong","year":"2017","unstructured":"Chong CR, Bahcall M, Capelletti M, et al. Identification of existing drugs that effectively target NTRK1 and ROS1 rearrangements in lung cancer. Clin Cancer Res. 2017;23(1):204\u201313.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"1131_CR19","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1007\/s12094-020-02376-w","volume":"22","author":"E Dudnik","year":"2020","unstructured":"Dudnik E, Agbarya A, Grinberg R, et al. Clinical activity of brigatinib in ROS1- rearranged non-small cell lung cancer. Clin Transl Oncol. 2020;22(12):2303\u201311.","journal-title":"Clin Transl Oncol"},{"issue":"8","key":"1131_CR20","doi-asserted-by":"crossref","first-page":"103642","DOI":"10.1016\/j.esmoop.2024.103642","volume":"9","author":"S Niho","year":"2024","unstructured":"Niho S, Goto K, et al. Phase II study of brigatinib in patients with ROS1 fusion-positive non-small cell lung cancer: the Barossa study. ESMO Open. 2024;9(8):103642.","journal-title":"ESMO Open."}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01131-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-025-01131-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01131-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T02:13:34Z","timestamp":1743041614000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-025-01131-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1131"],"URL":"https:\/\/doi.org\/10.1007\/s11523-025-01131-x","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"type":"print","value":"1776-2596"},{"type":"electronic","value":"1776-260X"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"3 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jean Mourlanette, Julien Mazieres, and Siham Mallah wrote this article, centered the data in Toulouse, and made statistical analyses. Gaelle Rousseau-Bussac and Christos Chouaid promoted the study, and helped retrieving data. All co authors participated in data collection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contribution"}},{"value":"No external funding was used in the preparation of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors were asked to make their statement of potential conflicts of interest on the site . Jean\u00a0Mourlanette, Gaelle\u00a0Rousseau-Bussac, Siham\u00a0Mallah, Florian\u00a0Guisier, Gerard\u00a0Zalcman, R\u00e9mi\u00a0Veillon, Clarisse\u00a0Audigier-Valette, Magali\u00a0Roa, Isabelle\u00a0Nicolle, Helene\u00a0Doubre, Nicolas\u00a0Cloarec, R\u00e9gine\u00a0Lamy, Hugues\u00a0Morel, Hubert\u00a0Curcio, Aur\u00e9lie\u00a0Lagrange, Roland\u00a0Schott, Marielle\u00a0Sabatini, Anne Claire\u00a0Toffart, Julian\u00a0Pinsolle, Jaafar\u00a0Bennouna, Christos\u00a0Chouaid, and Julien\u00a0Mazieres declare that they have no conflicts of interest that might be relevant to the contents of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The ethics committee of the Soci\u00e9t\u00e9 de Pneumologie de Langue Fran\u00e7aise approved the study (number: CEPRO 2021-002).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable, a letter of information was given to patients alive.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}